TARS (Tarsus Pharmaceuticals) Interest Expense: $-8.2 Mil (TTM As of Mar. 2026)

What is Tarsus Pharmaceuticals Interest Expense?

Tarsus Pharmaceuticals TARS -2.21% 48 Interest Expense is $-8.2 Mil as of Mar. 2026. GuruFocus rates TARS with a GF Score™ of 48/100 and a GF Value™ of $202.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tarsus Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was $ -2.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Tarsus Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $ -6.1 Mil. Tarsus Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $ -2.0 Mil. Tarsus Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tarsus Pharmaceuticals (NAS:TARS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tarsus Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $-2.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-6.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $72.6 Mil.

Tarsus Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Tarsus Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Tarsus Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Interest Expense can be seen below:

Tarsus Pharmaceuticals Interest Expense Chart

Tarsus Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

0.00

-2.06

-3.23

-7.45

-8.34

Tarsus Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-2.07	-2.09	-2.12	-2.06	-1.97

48GF Score

Tarsus Pharmaceuticals Inc TARS

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tarsus Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.2 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-8.2 Mil mean?

Tarsus Pharmaceuticals (TARS) has a Interest Expense of $-8.2 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tarsus Pharmaceuticals and its competitors.

Is Tarsus Pharmaceuticals' Interest Expense too high?

Tarsus Pharmaceuticals' current Interest Expense is $-8.2 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Tarsus Pharmaceuticals' Interest Expense compare to VERA and IDYA?

Tarsus Pharmaceuticals' Interest Expense of $-8.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Interest Expense is $-8.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tarsus Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $202.09, compared to a current price of $62.92 — trading 68.9% below its estimated fair value. The current Interest Expense is $-8.2 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Interest Expense is $-8.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $62.92 is trading 68.9% below its estimated GF Value™ of $202.09. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

Interest Expense: $-8.2 Mil
GF Value™: $202.09 vs. price of $62.92 (68.9% below fair value)
GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies VERA IDYA MLYS DFTX IMNM CLDX IRON ARQT ELVN RARE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618

Website https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

48GF Score

Get the complete analysis for TARS

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$62.92

Price

$202.09

GF Value

View TARS Analysis

See Interest Expense data for all stocks →